Combating Endometriosis related pain with $100K
Congratulations to Dr Thomas Tapmeier of the Uterine Biology and Gynaecological Diseases group at the Department of Obstetrics and Gynaecology, who has been awarded a combined $100K from Therapeutic Innovation Australia (TIA) and the Monash Research Impact Fund (MRIF) to develop new antagonists against the Neuropeptide S Receptor 1 (NPSR1).
“I am delighted! This is a wonderful opportunity to drive the search for new and better treatments for endometriosis — and other indications — forward. We are fortunate to have initiatives like TIA and the MRIF here, which enable speedy progress towards translation,” said Dr Tapmeier.
Having identified NPSR1 as a novel, non-hormonal target in endometriosis in collaboration with Bayer AG while at the Nuffield Department of Women’s & Reproductive Health at the University of Oxford, Dr Tapmeier formed a collaboration with Prof Jonathan Baell of the Monash Institute of Pharmacological Sciences (MIPS) to raise funding for medicinal chemistry on antagonists and a screening campaign.
It is hoped that this will lead to new therapeutics against endometriosis-related pain and inflammation.
About Monash University
Monash University is Australia’s largest university with more than 80,000 students. In the 60 years since its foundation, it has developed a reputation for world-leading high-impact research, quality teaching, and inspiring innovation.
With four campuses in Australia and a presence in Malaysia, China, India, Indonesia and Italy, it is one of the most internationalised Australian universities.
As a leading international medical research university with the largest medical faculty in Australia and integration with leading Australian teaching hospitals, we consistently rank in the top 50 universities worldwide for clinical, pre-clinical and health sciences.
For more news, visit Medicine, Nursing and Health Sciences or Monash University.
MEDIA ENQUIRIES